Interesting daySo it was an interesting day.
The reason I say this is the close of $2.15 cdn and volume of 73,165 vs. average daily volume of 33,300 shares. I find this interesting because normally after a presentation the share price is either not impacted or it drops.
I have no idea of whether the Cowen & Co's 37th Annual Health Care Conference presentation had an impact on today's surge but it is a pleasant surprise. If I recall correctly this is the third surge in volume at the new plus $2.00 since September 2016.
This price level and volume surges have been achieved without;
1. FDA BETonMACE approval to date but still in progress.
2. Announcement of a new licensing deal.
3. The apabetalone phase 2 trial in high risk (dialysis) CKD patients at this stage.
4. Approvals for orphan trials.
5. A NASDAQ listing.
6. Financing for the line of credit.
7. Etc.
So my feeling is that BETi and specifically Resverlogix apabetalone BET inhibitors are beginning to take traction within investors that want in at this low price level.
Recent presentations by RVX have pointed out the exponential growth in epigenetic scientific research papers being published and in specific terms related to apabetalone the FSHD muscular dystrophy positive research and the retinitis pigmentosis research done by unsponsored independent academic scientists are building credibility for this area of science.
Don stated that these types of findings are potential for licensing deals. How wonderful. Royalties flow to Resverlogix, which in turn flow to Zenith Capital…more opportunity for increased research and development.
I'm not a scientist but I am a science junky. CRISPR gets very high recognition and profile as a very hopeful approach, but everything I’ve read about it is that while it provides very accurate gene splicing and replacement, success has been very limited, and it is engineering of the hardware, whereas epigenetics engineers the software to control how the hardware (including broken hardware) functions.
What I am excited about is that back in January of 2016 I was posting about what a long journey it was going to be until the BETonMACE trial was complete in mid 2018. I naively felt that nothing in terms of scientific discovery relating to apabetalone would be of value other than the final BoM lll findings. How wrong I was. What we are seeing now is a dramatic acceleration of epigenetic research papers being published academically. As noted above, we are now seeing independent academic research papers about apabetalone on alternative indications/diseases. I am sure this will accelerate because of the positive results to date. Professors look for potential royalties.
It is the growth in intellectual/scientific momentum that will drive credibility and interest in the IP at RVX and Zenith. It is not just what they have in terms of compounds but “how they got there”.
Unique - We know that apabetalone is the only BETi involved in cardiovascular diseases and this seems to support Don’s claim of a 9 year intellectual lead in this “unmet” needs sector.
Anyway, just thinking out loud again and rambling.
GLTA
Toinv